A comparative study to evaluate effects on HCV-RNA-PCR by current oral anti-viral therapy with Sofosbuvir and Daclatasvir in Hepatitis C patients with and without Diabetes Melitis in Pakistan

Abstract

Objective: To compare the effects of antiviral therapy such as sofosbuvir and daclatasvir in HCV patients which were diagnosed by HCV-RNA PCR without Diabetes Melitis.
 Study Design: Cross-sectional comparative study
 Inclusion Criteria: HCV Positive patients after PCR test conformation between 20-75 years age.
 Methodology: In this cross-sectional analysis total of 100 Hepatitis c infected patients selected, Sofosbuvir plus Daclatasvir treatment given for 03 months period. Different parameters were recorded such as Total Bilirubin, Direct Bilirubin, Indirect Bilirubin, Hb levels, Serum ALT levels, and Serum ALP level. The statistical relation of the mentioned variables was analyzed through SPSS version 15.
 Results: Out of a total of 100 patients, 47% (47) were males, 53% (53) were females, 44% (44) patients had a history of prior interferon therapy, 23% (23) patients were having low hemoglobin levels before starting treatment. Both groups completed oral antiviral treatment for 12 weeks & resulting data showed the equality of treatment on group B and group A as no decrease in hemoglobin (p=0.799), ALT normalization (p=1.000) & no rise in serum bilirubin (p=0.817) during 1st month of treatment was noted in both groups while the SVR noted of both groups also showed no significant difference to each other i.e. 92% & 94 % (p=0.696).
 Conclusion: This study concluded to monitor the anti-viral drug response against HCV patients.